U.S. appeals court blocks overseas import of Gilead drugs, dealing blow to AFP health programs

A U.S. appeals court has ruled in favour of Gilead Sciences against companies running alternative funding programs (AFPs) that imported the firm's medicines from overseas at lower prices. The ruling blocks these programs from importing Gilead drugs from other countries. The decision is a significant blow to patients who relied on cheaper treatment-financing alternatives.